ATOS Earnings & Financial Statements
Atossa Therapeutics, Inc.
$2.78
+$0.22(+8.59%)
40
Overall
60
Value
50
Tech
10
Quality
Market Cap
$27.74M
Volume
235.94K
52W Range
$1.70 - $17.25
Target Price
$17.00
ATOS earnings and financial statements: Atossa Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ATOS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$37.14M | -$27.62M | -$31.38M | -$27.69M | -$20.52M |
| EBITDA | -$34.93M | -$25.47M | -$30.10M | -$27.68M | -$20.50M |
| Net income | -$34.80M | -$25.50M | -$30.09M | -$26.96M | -$20.61M |
| EPS (diluted) | $-4.04 | $-3.00 | $-3.60 | $-3.15 | $-2.70 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $47.61M | $76.44M | $96.25M | $123.53M | $141.26M |
| Total liabilities | $8.26M | $4.97M | $5.24M | $5.57M | $3.13M |
| Shareholders’ equity | $39.35M | $71.48M | $91.02M | $117.96M | $138.14M |
| Cash and equivalents | $41.30M | $71.08M | $88.46M | $110.89M | $136.38M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$29.76M | -$21.03M | -$20.94M | -$20.76M | -$16.47M |
| Capital expenditure | -$23.0K | -$19.0K | -$14.0K | -$27.0K | -$9.0K |
| Free cash flow | -$29.79M | -$21.05M | -$20.95M | -$20.79M | -$16.48M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ATOS | $2.78 | +8.6% | 235.94K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Atossa Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW